Overview Request Sample Pages Request Customization Download PDF
You are viewing: India Veterinary Biologics Market analysis
Part of: Veterinary Biologics Market (Global)

The India Veterinary Biologics Market was valued at $20.41 Million in 2025 and projected to reach to $27.07 Million by 2030, representing a compound annual growth rate of 5.8%. India's veterinary biologics market is positioned for sustained growth driven by the country's massive livestock base, thriving dairy industry, and emerging companion animal segment.

India Veterinary Biologics Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

India Veterinary Biologics Market Trends and Insights

  • This growth trajectory reflects India's increasing focus on animal health, livestock productivity, and disease prevention across dairy, poultry, and companion animal segments.
  • India's rising middle-class pet ownership and intensified agricultural practices are driving demand for advanced biological vaccines and immunological products. The Indian veterinary biologics sector benefits from a large livestock population and growing awareness of preventive healthcare in animals.
  • India's market expansion is supported by government initiatives promoting animal welfare and food security, alongside rising investments in veterinary infrastructure.
  • Between 2025 and 2030, India is expected to witness accelerated adoption of modern biologics, driven by regulatory improvements and increased accessibility to veterinary services across rural and urban regions. India's position within the Asia Pacific region underscores its significance as a high-growth market for veterinary biologics.
  • The country's competitive manufacturing base and emerging research capabilities position India as both a consumer and potential exporter of veterinary biological products in the coming years..

Key Market Statistics

  • CAGR (2025-2030) 5.8% CAGR
  • Market Size, 2025 ~USD 20.41 Million
  • Forecast, 2030 ~USD 27.07 Million
  • Country India

India Veterinary Biologics Market Overview

Market Valuation Growth :

India's veterinary biologics market is valued at USD 20.41 million in 2025, with a projected CAGR of 5.8% through 2030, reaching USD 27.07 million. This outpaces the global CAGR of 5.2%, indicating India's accelerating adoption of advanced veterinary biologics.

Livestock & Dairy Expansion :

India's dairy and livestock sectors are driving demand for veterinary biologics through intensified agricultural practices and disease prevention initiatives. The country's position as a global dairy leader necessitates robust animal health solutions to maintain productivity and export competitiveness.

Rising Pet Ownership Trends :

India's expanding middle class is fueling companion animal segment growth, with increasing pet ownership in urban centers like Mumbai, Delhi, and Bangalore. This demographic shift creates new opportunities for preventive care and specialized veterinary biologics targeting pet health.

Government & Regulatory Support :

India's government initiatives promoting animal health, disease surveillance programs, and livestock welfare regulations are strengthening the veterinary biologics market. Regulatory frameworks are evolving to support domestic manufacturing and innovation in veterinary immunologics.

India Veterinary Biologics Market Dynamics

  • Government support for animal health infrastructure and disease prevention programs, combined with increasing farmer awareness of preventive care benefits, will accelerate market expansion.
  • The rising middle-class pet ownership trend in metropolitan areas presents additional growth avenues for specialized biologics. Key growth catalysts include intensified agricultural practices requiring disease management solutions, export-driven quality standards for dairy and poultry products, and growing investment in veterinary research and development.
  • India's cost-competitive manufacturing capabilities and emerging domestic players will enhance market accessibility, while regulatory harmonization with international standards will facilitate innovation and market penetration across livestock and companion animal segments through 2030..

Related Ecosystem

Animal Health

Top Technologies
  • Polymerase Chain Reaction (PCR) Tests
  • Porcine
  • Immunodiagnostics
  • Lateral Flow Assays
  • Microarrays
Top Companies
  • Zoetis Inc.
  • Patterson Companies, Inc.
  • Virbac
  • Elanco Animal Health Incorporated
  • BOEHRINGER INGELHEIM GMBH

    Key Takeaways

    • India's veterinary biologics market is valued at USD 20.41 million in 2025 and is forecast to grow to USD 27.07 million by 2030, representing a 5.8% CAGR.
    • India's large livestock population and expanding companion animal segment are primary drivers of veterinary biologics demand.
    • Government initiatives and improved regulatory frameworks in India are accelerating market adoption and accessibility of veterinary biological products.
    • India's manufacturing capabilities position the country as a key player in veterinary biologics production within the Asia Pacific region.

    Veterinary Biologics Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment CANINE (Type)
    Forecast Period 2025–2030
    Growth Rate CAGR of 5.2% from 2025 to 2030
    Largest Segment INJECTABLE ROUTE OF ADMINISTRATION (Route Of Administration)
    Market Size Base Year (Billions) ~USD 2.72 (2025)
    Revenue Forecast (Billions) ~USD 3.51 (2030)
    Segments Covered Product Type, Animal Type, Type, Route Of Administration, Application, End User

    India Veterinary Biologics Market Report Segmentation

    6 segment dimensions are covered across the global market.

    By Product Type

    • Diagnostic Kits
    • Immunodmodulators & Immunostimulants
    • Immunoglobulins & Antitoxins
    • Immunomodulators & Immunostimulants
    • Immuoglobulins & Antitoxins
    • Monoclonal Anitbodies
    • Monoclonal Antibodies

    By Animal Type

    • Companion Animal
    • Companion Animals
    • Livestock Animal
    • Livestock Animals

    By Type

    • Bovine
    • Canine
    • Equine
    • Feline
    • Intramuscular Route Of Administration
    • Intravenous Route Of Administration
    • Other Injectable Route Of Administration
    • Porcine
    • Poultry
    • Small Ruminant
    • Subcutaneous Route Of Administration

    By Route Of Administration

    • Injectable Route Of Administration
    • Oral Route Of Administration
    • Other Routes Of Administration

    By Application

    • Dermatology
    • Diagnostic Testing
    • Diagnostic Tetsing
    • Infectious Disease Prevention
    • Oncology
    • Other Applications
    • Pain Management

    By End User

    • Other End Users
    • Veterinary Diagnostic Labs
    • Veterinary Hospitals & Clinics

    INDIA: VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    OTHER END USERS1.851.891.941.992.042.112.182.263.2
    VETERINARY DIAGNOSTIC LABS10.4510.7511.0911.4711.912.3712.913.474
    VETERINARY HOSPITALS & CLINICS35.7937.3839.1241.0743.245.5848.2351.15.5
    TOTAL48.0950.0252.1554.5357.1460.0563.3266.835.1

    Target Audience

    • Veterinary Biologics Manufacturers : Manufacturers need India-specific market data to assess expansion opportunities, understand regulatory requirements, and identify distribution partnerships in livestock, dairy, and companion animal segments.
    • Livestock & Dairy Producers : Indian farmers and dairy cooperatives require insights into available biologics solutions, disease prevention strategies, and cost-effective vaccination programs to enhance productivity and meet export quality standards.
    • Veterinary Pharmaceutical Companies : Pharma companies need competitive intelligence on India's veterinary biologics market to develop localized product portfolios, pricing strategies, and go-to-market approaches for livestock and pet health segments.
    • Pet Care & Companion Animal Businesses : Pet healthcare providers and veterinary clinics in urban India need market data on companion animal biologics demand, premium product opportunities, and consumer spending trends in growing metropolitan markets.
    • Investment & Consulting Firms : Investors and consultants require India-specific market forecasts, growth drivers, and competitive landscape analysis to identify investment opportunities and advise clients on veterinary biologics sector expansion.

    Key Companies in the India Veterinary Biologics Market

    CompanyHQOwnershipStrongest segments
    IDEXXUnited StatesPublic CompanyCompanion Animal Group (in-clinic diagnostics, reference labs, services, software),Water Quality Products,Livestock, Poultry and Dairy (including related diagnostics),
    ELANCOUnited StatesPublic CompanyCompanion animal parasiticides (Seresto, K-9 Advantage, Advantix, Advocate, Credelio Family, Interceptor Plus, Drontal),Companion animal vaccines and therapeutics (Galliprant, Atopica, Milbemax, Onsior, Tru Family),Farm animal feed additives and productivity enhancers (Rumensin, Experior, Hemicell, Surmax, Pulmotil),
    MERCK & CO., INC.United StatesPublic CompanyOncology (Keytruda, Keytruda Qlex, Welireg, ADC collaborations),Vaccines (Gardasil, pediatric and adult vaccines including Vaxneuvance, Capvaxive),Cardiovascular, pulmonary hypertension and specialty (Winrevair, Adempas/Verquvo, Ohtuvayre, others),
    THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
    NEOGEN CORPORATIONUnited StatesPublic CompanyFood Safety diagnostics, media, and sanitation,Animal Safety instruments, care products, and biosecurity,Genomics services for livestock and companion animals,
    BIO-RAD LABORATORIES, INC.United StatesPublic CompanyClinical Diagnostics,Life Science Research Instruments and Systems,Life Science Reagents and Consumables,
    IMMUCELL CORPORATIONUnited StatesPublic CompanyFirst Defense (core scours prevention),Tri-Shield First Defense,Dual-Force First Defense and related formulations,

    IDEXX

    IDEXX is a public company founded in 1983 and headquartered in the United States, employing 11,000 people.

    ELANCO

    Elanco is a public company founded in 1954 in the United States with 9,650 employees.

    MERCK & CO., INC.

    Merck & Co., Inc. is a public pharmaceutical company founded in 1891 and based in the United States, with 74,000 employees.

    THERMO FISHER SCIENTIFIC INC.

    Thermo Fisher Scientific Inc. is a public company founded in 1956 in the United States and employs 125,000 people.

    NEOGEN CORPORATION

    Neogen Corporation is a public company founded in 1981 in the United States with 2,974 employees.

    BIO-RAD LABORATORIES, INC.

    Bio-Rad Laboratories, Inc. is a public company founded in 1952 in the United States and employs 7,450 people.

    IMMUCELL CORPORATION

    ImmuCell Corporation is a public company founded in 1982 in the United States with 73 employees.

    Reasons to Buy this Report

    • Livestock Sector Intelligence : Gain comprehensive insights into India's dairy and poultry biologics demand, enabling strategic positioning in the world's largest dairy market. Understand disease prevention trends and vaccination adoption patterns across India's extensive livestock base.
    • Emerging Pet Care Opportunities : Identify high-growth companion animal segments in urban India where pet ownership is surging. Access data on premium pet biologics demand in metropolitan markets and emerging consumer willingness to invest in preventive pet healthcare.
    • Regulatory & Manufacturing Landscape : Navigate India's evolving veterinary biologics regulatory framework and identify manufacturing opportunities. Understand government support mechanisms, quality standards, and pathways for domestic and international market entry.
    • Competitive Market Positioning : Benchmark against local and international players in India's veterinary biologics space. Identify market gaps, pricing strategies, and distribution channels specific to India's diverse agricultural and urban animal health segments.
    • Growth Forecasting & Strategy : Leverage India-specific CAGR projections (5.8%) and segment forecasts through 2030 to develop targeted expansion strategies. Make informed investment decisions backed by granular market data and regional growth drivers.

    Frequently asked questions

    What is the current size of India's veterinary biologics market?

    India's veterinary biologics market is valued at USD 20.41 million in 2025 and is expected to grow at a 5.8% CAGR through 2030.

    What is the projected market size for India's veterinary biologics by 2030?

    India's veterinary biologics market is projected to reach USD 27.07 million by 2030, up from USD 20.41 million in 2025.

    What are the main drivers of growth in India's veterinary biologics market?

    Key drivers in India include a large livestock population, rising pet ownership, government animal welfare initiatives, and improved veterinary infrastructure and regulatory frameworks.

    How does India's veterinary biologics market compare to the global market?

    India's market is growing at 5.8% CAGR, slightly outpacing the global average of 5.2%, reflecting strong regional demand and emerging market dynamics.

    What role does India play in the Asia Pacific veterinary biologics market?

    India is a significant high-growth market within Asia Pacific, with competitive manufacturing capabilities and potential to serve as both a regional consumer and exporter of veterinary biological products.

    RESEARCH METHODOLOGY

    This study extensively used both primary and secondary sources. The research process examined various factors affecting the industry to identify segmentation types, industry trends, key players, competitive landscape, market dynamics, and strategies of major players.

    Secondary Research

    This research involved the use of comprehensive secondary sources, including directories; databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was employed to gather information for an extensive, technical, market-focused, and commercial analysis of the veterinary biologics market. It also helped obtain crucial details about key players, market classification, and segmentation based on industry trends at the most detailed levels, as well as significant developments related to market and technology perspectives. Additionally, a database of major industry leaders was created using secondary research.

    Primary Research

    In the primary research process, various sources from both the supply and demand sides were interviewed to gather qualitative and quantitative information for this report. Primary sources from the supply side include project managers, sales managers, marketing managers, business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the veterinary biologics market. Primary sources from the demand side consist of professionals from veterinary hospitals and clinics, diagnostic labs, academic and research institutes, and pet owners.

    A breakdown of the primary respondents is provided below:

    Veterinary Biologics Market

    Note 1: C-level primaries include CEOs, CFOs, COOs, and VPs.

    Note 2: Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

    Note 3: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = < USD 1.00 billion.

    Source: MarketsandMarkets Analysis

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The total size of the veterinary biologics market was determined through data triangulation from three different approaches, as outlined below. After each approach, a weighted average was calculated based on the level of assumptions used in each method.

    Veterinary Biologics Market

    Data Triangulation

    After defining the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown methods were used where applicable to complete the overall market analysis and determine accurate statistics for all segments and subsegments. The following figure illustrates the market validation, source structure, and data triangulation approach used in the market analysis process.

    Market Definition

    The veterinary biologics market includes all USDA-regulated biologic products, such as monoclonal antibodies, immunoglobulins, immunomodulators, and diagnostic kits, which are used for the prevention, diagnosis, or treatment of animal diseases. These products serve companion animals, livestock, and poultry across veterinary clinics, hospitals, diagnostic labs, and farm or herd settings, enabling veterinarians and animal health professionals to provide targeted immune-based interventions and rapid diagnostic testing. This allows infected animals to be identified quickly for faster treatment, containment, or herd management decisions.

    Stakeholders

    • Veterinary Biologics Manufacturers
    • Animal Healthcare Product Manufacturers
    • Veterinary Biologics Distributors and Wholesalers
    • Animal Welfare Associations
    • Veterinary Clinics and Care Centers
    • Research And Consulting Firms
    • Veterinary Research and Development Organizations
    • Contract Manufacturing Organizations
    • Venture Capitalists

    Report Objectives

    • To define, describe, and forecast the veterinary biologics market by product type, animal type, route of administration, application, end user, and region.
    • To provide detailed information about the key factors, such as drivers, restraints, opportunities, challenges, and industry trends, influencing the market growth
    • To strategically analyze the regulatory scenario, value chain analysis, supply chain analysis, Porter’s Five Forces analysis, ecosystem analysis, trade analysis, pricing analysis, patent analysis, impact of AI on veterinary biologics market, case study analysis, adjacent market analysis, unmet needs/end user expectations in veterinary biologics market, and trends/disruption impacting customer business in the market
    • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
    • To strategically analyze the market in five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
    • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
    • To strategically profile the key players in this market and comprehensively analyze their market shares and core competencies
    • To track and analyze competitive developments such as product launches and approvals, partnerships, and expansions in the market

     

    Get the Full Veterinary Biologics Market Report

    Full forecast, segment splits, and company analysis for all Veterinary Biologics Market.

    Download Sample Pages Buy Report

    METHODOLOGY

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    Cite this Research
    DMCA.com Protection Status